In addition, MLs extract demonstrated dose‐dependent inhibitory effects on acetylcholinesterase (AChE, IC50: 18.73 μg/mL), butyrylcholinesterase (BChE, IC50: 8.56 μg/mL), and α‐glucosidase (IC50: 10.83 μg/mL), highlighting its potential in the management of neurodegenerative diseases such as Alzheimer's and metabolic disorders including diabetes. Here, ACHE is linked to diabetes mellitus.